

QIBA Process Committee Meeting

March 21, 2023, at 2 pm (CT)

Meeting Summary

Attendees:

Michael Boss, PhD (Vice Chair)

J. Brian Fowlkes, PhD

Timothy Hall, PhD

Nancy Obuchowski, PhD

Dan Sullivan, MD

RSNA Staff:

Susan Stanfa

Next Steps / Action Items:

CC Co-Chair Role: Screening New BC Proposals

- The number of Biomarker Committees has increased during the past few years to a total of 23; QIBA has partnered with other societies for admin support for four of them
- To ensure that new BCs progress from Stage 0 to Stage 1 within ~18-24 months, all new biomarker proposals should contain a robust plan of action for Profile development including:
 - Clear QIBs
 - A sense of the Claim language
 - Well-identified leadership and initial cohort of reliable BC members
 - Broad stakeholder buy-in and clinician involvement
 - 5–6-page digestible proposal that addresses QIBA criteria
- A standard, rigorously defined application screening process at the CC Co-Chair level is needed
 - For 129Xe, MR CC Co-chairs used a hands-on approach to aid with proposal development prior to presentation to the CC for member evaluation / scoring
 - Though the screening process was lengthy compared to past BC proposals, it ensured enthusiastic CC and SC support and a streamlined Profile-writing process within the first 6-12 months
 - It was noted that BCs with the most rapid Profile advancement had partnered with QIBA process SMEs during Profile development

Next Process Cmte Meeting on Tuesday, April 4, 2023, at 2 p.m. CT

- Review of Stage 4 requirements to resume with reference to a specific Profile, Claim, and criteria